FERAHEME® (ferumoxytol injection) Billing and Coding Information for Outpatient Services*

FERAHEME is indicated for the treatment of iron deficiency anemia (IDA) in adult patients:

- who have intolerance to oral iron or have had unsatisfactory response to oral iron or
- who have chronic kidney disease (CKD)

FERAHEME product and administration codes

HCPCS[1]	Injection, ferumoxytol, for treatment of IDA, 1 mg **Q0138** non-ESRD use **OR Q0139** ESRD on dialysis
Drug administration CPT® codes[2†]	**96365** Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
National Drug Codes (NDC)[3‡]	**59338-0775-01** FERAHEME 510 mg/17 mL, 1 vial **59338-0775-10** FERAHEME 510 mg/17 mL, 10 vials

*This table is provided for informational purposes only. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and specific billing requirements. AMAG Pharmaceuticals, Inc. does not make any representation or guarantees concerning reimbursement or coverage for any service or item.

†CPT® is a registered trademark of the American Medical Association.

‡Payer requirements regarding 10-digit and 11-digit NDC may vary.

CPT: Current Procedural Terminology; ESRD: end-stage renal disease; HCPCS: Healthcare Common Procedure Coding System.

Feraheme® (ferumoxytol injection) Important Safety Information

WARNING: RISK FOR SERIOUS HYPERSENSITIVITY/ANAPHYLAXIS REACTIONS

Fatal and serious hypersensitivity reactions including anaphylaxis have occurred in patients receiving Feraheme. Initial symptoms may include hypotension, syncope, unresponsiveness, cardiac/cardiorespiratory arrest.

- **Only administer Feraheme as an intravenous infusion over at least 15 minutes and only when personnel and therapies are immediately available for the treatment of anaphylaxis and other hypersensitivity reactions.**
- **Observe for signs or symptoms of hypersensitivity reactions during and for at least 30 minutes following Feraheme infusion including monitoring of blood pressure and pulse during and after Feraheme administration.**
- **Hypersensitivity reactions have occurred in patients in whom a previous Feraheme dose was tolerated.**

Please see additional **Important Safety Information** throughout, and full **Prescribing Information**, including **Boxed Warning**, in pocket.

For questions regarding the billing and coding information above or for resources to support the claims appeal process, call: 844-635-AMAG (2624)
Website: Feraheme.com

Feraheme®
ferumoxytol injection

Product, Administration, and Diagnosis Codes*

HCPCS[1]	Injection, ferumoxytol, for treatment of IDA, 1 mg **Q0138** non-ESRD use **OR Q0139** ESRD on dialysis
Drug administration CPT® codes[2†]	**96365** Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
National Drug Codes (NDC)[3‡]	**59338-0775-01** FERAHEME 510 mg/17 mL, 1 vial **59338-0775-10** FERAHEME 510 mg/17 mL, 10 vials
Diagnosis codes (ICD-10)[4]	D50.0 Blood loss (chronic) D50.1 Sideropenic dysphagia D50.8 Poor iron absorption D50.9 Iron deficiency anemia, unspecified **Confirm iron deficiency before using the following codes:** D63.0 Anemia in neoplastic disease CODE NEOPLASM FIRST D63.1 Anemia in chronic kidney disease CODE CKD STAGE D63.8 Anemia in other chronic diseases classified elsewhere CODE UNDERLYING DISEASE FIRST D64.81 Antineoplastic chemotherapy-induced anemia

Feraheme Important Safety Information (cont'd)

Contraindications

Feraheme is contraindicated in patients with known hypersensitivity to Feraheme or any of its components or a history of allergic reaction to any intravenous iron product.

Warnings and Precautions

Hypersensitivity: In addition to the fatal and serious adverse reactions in the Boxed Warning, other adverse reactions associated with hypersensitivity have occurred (pruritus, rash, urticaria, and wheezing). Allergic reactions have occurred following the first dose or subsequent doses in patients in whom a previous dose was tolerated. Patients with a history of multiple drug allergies may have a greater risk of anaphylaxis with parenteral iron products. Carefully consider the potential risks and benefits before administering Feraheme to these patients. Elderly patients with multiple or serious co-morbidities who experience hypersensitivity reactions and/or hypotension following administration of Feraheme may have more severe outcomes.

Please see additional **Important Safety Information** throughout, and accompanying full **Prescribing Information**, including **Boxed Warning**, in pocket.

Codes Pertaining to IDA Underlying Conditions*

Diagnosis codes (ICD-10)[4]	E83.10 Iron metabolism E83.19 Other disorders of iron metabolism, specified NEC K50.00, K50.90, K50.919 Crohn's disease (regional enteritis) K51.00, K51.90, K51.919 Pancolitis, ulcerative colitis, complication K90.0 Celiac disease K90.49 Malabsorption due to intolerance K90.89 Intestinal malabsorption, specified NEC K90.9 Intestinal malabsorption N18.1 CKD, stage 1 N18.2 CKD, stage 2 N18.3 CKD, stage 3 N18.4 CKD, stage 4 N18.5 CKD, stage 5 N18.6 CKD, end-stage (failure) N18.9 CKD N92.0, N92.6 Excessive, frequent, and irregular menstruation N95.0 Postmenopausal bleeding T45.4X5 [A,S,D] Adverse effect of iron and its compounds T50.905 [A,S,D] Adverse effect of unspecified drugs, medicaments, and biological substances

*This table is provided for informational purposes only. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and specific billing requirements. AMAG Pharmaceuticals, Inc. does not make any representation or guarantees concerning reimbursement or coverage for any service or item.

†CPT® is a registered trademark of the American Medical Association.

‡Payer requirements regarding 10-digit and 11-digit NDC may vary.

CKD: chronic kidney disease; NEC: not elsewhere classified; ICD: International Classification of Diseases.

Feraheme® ferumoxytol injection

Feraheme Important Safety Information (cont'd)

Warnings and Precautions (cont'd)

Hypotension: Feraheme may cause clinically significant hypotension. Monitor patients for signs and symptoms of hypotension following each Feraheme administration.

Iron Overload: Excessive therapy with parenteral iron can lead to excess storage of iron with the possibility of iatrogenic hemosiderosis. Regularly monitor the hematologic response during parenteral iron therapy. Do not administer Feraheme to patients with iron overload.

Magnetic Resonance (MR) Imaging Test Interference: Administration of Feraheme may transiently affect the diagnostic ability of MR imaging. Alteration of MR imaging studies may persist for up to 3 months following the last Feraheme dose. Maximum alteration of vascular MR imaging is anticipated to be evident for 1 – 2 days following Feraheme administration.

Adverse Reactions

The most common adverse reactions (≥ 2%) are diarrhea, headache, nausea, dizziness, hypotension, constipation, and peripheral edema.

Please see additional **Important Safety Information** throughout, and accompanying full **Prescribing Information**, including **Boxed Warning**, in pocket.

Visit Feraheme.com for more information.

References: 1. Centers for Medicare & Medicaid Services, US Department of Health and Human Services. HCPCS 2018 index. https://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Downloads/2018-HCPCS-Index.pdf. Updated February 15, 2018. Accessed April 9, 2018. **2.** American Medical Association. *Current Procedural Terminology 2017: Professional Edition*. Chicago. IL: American Medical Association; 2016. **3.** Feraheme [prescribing information]. AMAG Pharmaceuticals, Inc; February 2018. **4.** Centers for Medicare & Medicaid Services. 2018 code tables and index. https://www.cms.gov/Medicare/Coding/ICD10/Downloads/2018-ICD-10-Table-And-Index.zip. Accessed April 9, 2018.

AMAG Pharmaceuticals, Inc. 1100 Winter Street, Waltham, MA 02451

Feraheme® ferumoxytol injection